Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences, Inc. (NASDAQ: INBX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its biologic therapeutic candidates ozekibart (INBRX-109) and INBRX-106. The company’s press releases and SEC reports describe ongoing clinical trials in solid tumors, including chondrosarcoma, colorectal cancer, Ewing sarcoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
On this page, readers can follow company-issued updates on key clinical milestones, such as topline and interim data from the registrational ChonDRAgon study of ozekibart in unresectable or metastatic conventional chondrosarcoma and expansion cohorts in colorectal cancer and Ewing sarcoma. Inhibrx Biosciences also reports on progress in its INBRX-106 Phase 2/3 trial in combination with pembrolizumab in head and neck squamous cell carcinoma and its Phase 1/2 trial in checkpoint inhibitor refractory or relapsed non-small cell lung cancer.
News items further cover financial results, capital arrangements, and corporate developments following the company’s spin-off from Inhibrx, Inc. and the sale of the INBRX-101 program to Sanofi S.A. Investors and observers can review earnings releases, descriptions of research and development spending, and commentary on the company’s clinical and regulatory plans.
Because Inhibrx Biosciences focuses on oncology and, in some communications, rare diseases, its announcements often highlight data from difficult-to-treat patient populations and regulatory designations, such as Fast Track and orphan drug status for ozekibart in chondrosarcoma. Bookmark this news feed to access the company’s own descriptions of trial outcomes, conference presentations, and other material events as they are disclosed.
Oxford Finance has closed a $10 million senior secured term loan to Inhibrx (Nasdaq: INBX), a clinical-stage biotech company. This funding, finalized on July 15, 2020, is aimed at supporting Inhibrx's growth as it transitions into a commercial-stage biotechnology firm. Inhibrx is focused on developing innovative biologic therapies, with a pipeline of four Phase 1 clinical trials targeting cancer and respiratory diseases. Oxford previously partnered with Inhibrx, highlighting confidence in its clinical advancements.
Inhibrx, a clinical-stage biotechnology company, has successfully completed its initial public offering (IPO) of 8,050,000 shares, including an over-allotment of 1,050,000 shares, priced at $17.00 per share. This IPO generated approximately $136.9 million in gross proceeds. The stock began trading on the Nasdaq under the symbol INBX on August 19, 2020. Jefferies, Evercore ISI, and Credit Suisse were the joint book-running managers for the offering, with LifeSci Capital serving as co-manager. The prospectus for this offering is available from the managing firms.